Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 55.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 160,412 shares of the specialty pharmaceutical company’s stock after buying an additional 57,406 shares during the period. American Century Companies Inc.’s holdings in Jazz Pharmaceuticals were worth $19,755,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $25,000. Jones Financial Companies Lllp boosted its stake in Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after acquiring an additional 130 shares during the last quarter. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares in the last quarter. Lindbrook Capital LLC increased its position in shares of Jazz Pharmaceuticals by 82.6% in the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 176 shares during the last quarter. Finally, Itau Unibanco Holding S.A. raised its stake in shares of Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares in the company, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $137.81, for a total transaction of $157,103.40. Following the transaction, the chief accounting officer now directly owns 7,012 shares in the company, valued at approximately $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,736 shares of company stock worth $4,022,825. 4.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on JAZZ shares. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Piper Sandler reissued an “overweight” rating and set a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. HC Wainwright increased their target price on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $140.00 to $150.00 in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $122.92 on Monday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The firm has a market capitalization of $7.47 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The business has a 50 day simple moving average of $132.30 and a 200 day simple moving average of $122.66.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.